Science Corporation has raised $400 million in a Series D funding round, with investors valuing the medical technology company at $3.5 billion, according to a person familiar with the deal. The company says the new funding will support efforts to bring its vision-restoring device to the United States and its longer-term work on technology that interfaces directly with the brain.
Funding supports a vision device
Science Corporation was founded in 2021 by Max Hodak, a former Neuralink president. The company’s first product, PRIMA, is a wearable and implantable chip intended to help people with age-related macular degeneration recover some vision.
PRIMA is approved in Europe and available in Germany. The device is also being trialled for other conditions. Hodak announced at TechCrunch Disrupt that it is now being tested with patients who have Stargardt’s disease, another condition that causes blindness.
The company says it plans to use the new funding to pursue a route to US availability through the FDA’s Humanitarian Device Exemption. That pathway allows experimental medical technology to be used for rare conditions. Science has persuaded the FDA that advanced macular degeneration affecting both eyes is uncommon enough for the company to seek approval to use PRIMA in the United States.
From restoring vision to connecting with the brain
PRIMA is the company’s first product, but Science Corporation’s broader aim is to connect technology directly to the human brain. Its planned approach uses a bio-hybrid sensor made from cultured neurons and silicon.
The company is designing initial human trials of that sensor with Murat Günel, a Yale neurosurgery professor. Günel told TechCrunch the technology could offer potential treatments for Parkinson’s disease, as well as other brain injuries and illnesses.
The article describes the device as being in the trial-planning stage. The potential uses are therefore possibilities under investigation, rather than established treatments. The company’s work spans two different steps: advancing a device already available in Germany, and preparing to test a brain sensor in people.
Investors back a broader ambition
The funding round included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech. The reported $3.5 billion valuation reflects the investors’ assessment of the company in this financing round.
Hodak co-founded Science to use new technologies to understand and interact with the brain. The company’s effort to expand PRIMA and its research into a bio-hybrid sensor reflect that founding focus, though the source describes the sensor as still being prepared for initial human trials.
What the funding could make possible
The immediate goal is to seek a path for PRIMA’s use in the United States for advanced macular degeneration in both eyes. The FDA pathway cited by the company concerns rare conditions, and approval has not been described as already granted.
Further out, the planned human trials could help establish whether a sensor combining living neurons and silicon can safely and usefully interact with the brain. The source identifies Parkinson’s disease and other brain injuries and illnesses as possible areas of application, while leaving the device’s eventual role dependent on the work ahead.